Alzheimer’s disease, frontotemporal lobar degeneration, dementia with Lewy bodies, and Parkinson’s disease (PD) overlap in clinical characteristics, neuropathology, and genetics.
Objective:
The aim of this study was to evaluate the role of pathogenic mutations and rare variants in genes associated with PD among early-onset dementia (EOD) patients.
Methods:
Rare non-synonymous variants (MAF < 0.01) in ten genes (SNCA, PARK2, PARK7, LRRK2, PINK1, ATP13A2, UCHL1, HTRA2, GBA, and SNCAIP) and low-frequency (MAF < 0.05) GBA variants were screened using a targeted next-generation sequencing panel in a strictly defined cohort of 37 early-onset (age at onset (AAO) <65 years) dementia patients presenting with atypical features (e.g., myoclonia or spasticity), rapidly progressive course of the disease or with a family history of dementia. The identified variations were further screened in a larger cohort of EOD (n = 279, mean AAO 57, range 36–65) patients.
Results:
No pathogenic mutations were found, but we identified seven possible risk variants for neurodegeneration (LRRK2 p.Arg793Met, PARK2 p.Ala82Glu, SNCAIP p.Arg240Gln, SNCAIP p.Phe369Leu, GBA p.Asn409Ser, GBA p.Glu365Lys, GBA p.Thr408Met).
Discussion:
Altogether, the frequency of these variants was two times higher in the first selected cohort compared to the whole cohort. This suggests that specific rare variants in the genes associated with PD might play a role also especially in familial EOD.
Santos-RebouçasCB, AbdallaCB, BaldiFJ, MartinsPA, CorrêaJC, GonçalvesAP, CunhaMS, BorgesMB, PereiraJS, LaksJ, PimentelMM (2008) Co-occurrence of sporadic parkinsonism and late-onset Alzheimer’s disease in a Brazilian male with the LRRK2 p.G2019S mutation. Genet Test12, 471–473.
8.
GiauV Van, SenanarongV, BagyinszkyE, AnSSA, KimS (2019) Analysis of 50 neurodegenerative genes in clinically diagnosed early-onset Alzheimer’s disease. Int J Mol Sci20, 1514.
9.
NallsMA, DuranR, LopezG, Kurzawa-AkanbiM, McKeithIG, ChinneryPF, MorrisCM, TheunsJ, CrosiersD, CrasP, EngelborghsS, De DeynPP, Van BroeckhovenC, MannDM, SnowdenJ, Pickering-BrownS, HalliwellN, DavidsonY, GibbonsL, HarrisJ, SheerinUM, BrasJ, HardyJ, ClarkL, MarderK, HonigLS, BergD, MaetzlerW, BrockmannK, GasserT, NovellinoF, QuattroneA, AnnesiG, De MarcoEV, RogaevaE, MasellisM, BlackSE, BilbaoJM, ForoudT, GhettiB, NicholsWC, PankratzN, HallidayG, LesageS, KlebeS, DurrA, DuyckaertsC, BriceA, GiassonBI, TrojanowskiJQ, HurtigHI, TayebiN, LandazabalC, KnightMA, KellerM, SingletonAB, WolfsbergTG, SidranskyE (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol70, 727–735.
CacaceR, SleegersK, Van BroeckhovenC (2016) Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement12, 733–748.
13.
MajounieE, RentonAE, MokK, DopperEG, WaiteA, RollinsonS, ChiòA, RestagnoG, NicolaouN, Simon-SanchezJ, van SwietenJC, AbramzonY, JohnsonJO, SendtnerM, PamphlettR, OrrellRW, MeadS, SidleKC, HouldenH, RohrerJD, MorrisonKE, PallH, TalbotK, AnsorgeO, Chromosome 9-ALS/FTD Consortium, French research network on FTLD/FTLD/ALS, ITALSGEN Consortium, HernandezDG, ArepalliS, SabatelliM, MoraG, CorboM, GianniniF, CalvoA, EnglundE, BorgheroG, FlorisGL, RemesAM, LaaksovirtaH, McCluskeyL, TrojanowskiJQ, Van DeerlinVM, SchellenbergGD, NallsMA, DroryVE, LuCS, YehTH, IshiuraH, TakahashiY, TsujiS, Le BerI, BriceA, DrepperC, WilliamsN, KirbyJ, ShawP, HardyJ, TienariPJ, HeutinkP, MorrisHR, Pickering-BrownS, TraynorBJ (2012) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study. Lancet Neurol11, 323–330.
14.
KaivorinneA-L, KrügerJ, KuivaniemiK, TuominenH, MoilanenV, MajamaaK, RemesAM (2008) Role of MAPT mutations and haplotype in frontotemporal lobar degeneration in Northern Finland. BMC Neurol8, 48.
15.
KrügerJ, KaivorinneA-L, UddB, MajamaaK, RemesAM (2009) Low prevalence of progranulin mutations in Finnish patients with frontotemporal lobar degeneration. Eur J Neurol16, 27–30.
McKhannG, KnopmanDS, ChertkowH, HymanB, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelphsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
ExcoffierL, LischerHEL (2010) Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour10, 564–567.
26.
BonferroniCE (1936) Teoria statistica delle classi e calcolo delle probabilità. Pubbl R Ist Super Sci Eco Commer Firenze8, 3–62.
27.
ReedX, Bandrés-CigaS, BlauwendraatC, CooksonMR (2019) The role of monogenic genes in idiopathic Parkinson’s disease. Neurobiol Dis124, 230–239.
28.
FatahianR, BagheriSR, SadeghiM (2019) A meta-analysis of leucine-rich repeat kinase 2 (LRRK2) polymorphisms in Alzheimer’s disease. Folia Neuropathol57, 1–5.
29.
BergD, SchweitzerK, LeitnerP, ZimprichA, LichtnerP, BelcrediP, BrusselT, SchulteC, MaassS, NägeleT, WszolekZK, GasserT (2005) Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson’s disease. Brain128, 3000–3011.
30.
Bandrés-CigaS, PriceTR, BarreroFJ, Escamilla-SevillaF, PelegrinaJ, ArepalliS, HernándezD, GutiérrezB, CervillaJ, RiveraM, RiveraA, DingJ-H, VivesF, NallsM, SingletonA, DuránR (2016) Genome-wide assessment of Parkinson’s disease in a Southern Spanish population. Neurobiol Aging45, 213.e3–213.e9.
31.
Chen-PlotkinAS, YuanW, AndersonC, WoodEM, HurtigHI, ClarkCM, MillerBL, LeeVM-Y, TrojanowskiJQ, GrossmanM, Van DeerlinVM (2008) Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology70, 521–527.
32.
CovyJP, YuanW, WaxmanEA, HurtigHI, Van DeerlinVM, GiassonBI (2009) Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. Mov Disord24, 32–39.
33.
ToftM, HaugarvollK, RossOA, FarrerMJ, AaslyJO (2007) LRRK2 and Parkinson’s disease in Norway. Acta Neurol Scand Suppl187, 72–75.
ZimmermannM, WilkeC, SchulteC, HoffmannJ, KlopferJ, ReimoldM, BrockmannK, SynofzikM (2018) Biallelic Parkin (PARK2) mutations can cause a bvFTD phenotype without clinically relevant parkinsonism. Parkinsonism Relat Disord55, 145–147.
37.
KayDM, MoranD, MosesL, PoorkajP, ZabetianCP, NuttJ, FactorSA, YuC-E, MontimurroJS, KeefeRG, SchellenbergGD, PayamiH (2007) Heterozygous parkin point mutations are as common in control subjects as in Parkinson’s patients. Ann Neurol61, 47–54.
38.
LesageS, LohmannE, TisonF, DurifF, DürrA, BriceA (2008) Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet45, 43–46.
39.
HåkanssonA, BelinAC, StillerC, SydowO, JohnelsB, OlsonL, HolmbergB, NissbrandtH (2008) Investigation of genes related to familial forms of Parkinson’s disease - with focus on the Parkin gene. Park Relat Disord14, 520–522.
40.
ErerS, EgeliU, ZarifogluM, TezcanG, CecenerG, TuncaB, AkS, DemirdogenE, KenangilG, KaleagasiH, DoguO, SakaE, ElibolB (2016) Mutation analysis of the PARKIN, PINK1, DJ1, and SNCA genes in Turkish early-onset Parkinson’s patients and genotype-phenotype correlations. Clin Neurol Neurosurg148, 147–153.
41.
XieYY, ZhouCJ, ZhouZR, HongJ, CheMX, FuQS, SongAX, LinDH, HuHY (2010) Interaction with synphilin-1 promotes inclusion formation of α-synuclein: Mechanistic insights and pathological implication. FASEB J24, 196–205.
42.
MyhreR, KlunglandH, FarrerMJ, AaslyJO (2008) Genetic association study of synphilin-1 in idiopathic Parkinson’s disease. BMC Med Genet9, 1–7.
43.
KeyserRJ, OpponE, CarrJA, BardienS (2011) Identification of Parkinson’s disease candidate genes using CAESAR and screening of MAPT and SNCAIP in South African Parkinson’s disease patients. J Neural Transm118, 889–897.
44.
BandopadhyayR, De SilvaR, KhanN, GrahamE, VaughanJ, EngelenderS, RossC, MorrisH, MorrisC, WoodNW, DanielS, LeesA (2001) No pathogenic mutations in the synphilin-1 gene in Parkinson’s disease. Neurosci Lett307, 125–127.
45.
BusbyJ, O’BrienKK, GibsonAM, McKeithIG, PerryRH, HardyJA, SingletonAB, MorrisCM (2004) Dementia with Lewy bodies: No association of polymorphisms in the human synphilin gene. Neurogenetics5, 251–252.
46.
MaraganoreDM, BowerJH, RoccaWA, LesnickTG, de AndradeM, FarrerMJ, HernandezD, HardyJA (2003) Case-control study of the α-synuclein interacting protein gene and Parkinson’s disease. Mov Disord18, 1233–1239.
47.
Berge-SeidlV, PihlstrømL, Maple-GrødemJ, ForsgrenL, LinderJ, LarsenJP, TysnesO-B, ToftM (2017) The GBA variant E326K is associated with Parkinson’s disease and explains a genome-wide association signal. Neurosci Lett658, 48–52.
48.
MallettV, RossJP, AlcalayRN, AmbalavananA, SidranskyE, DionPA, RouleauGA, Gan-OrZ (2016) GBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis. Neurol Genet2, e104.
49.
DavisAA, AndruskaKM, BenitezBA, RacetteBA, PerlmutterJS, CruchagaC (2016) Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiol Aging37, 209.e1–209.e7.
